PT  - JOURNAL ARTICLE
AU  - E Hachulla
AU  - J G Coghlan
TI  - A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
AID  - 10.1136/ard.2003.017673
DP  - 2004 Sep 01
TA  - Annals of the Rheumatic Diseases
PG  - 1009--1014
VI  - 63
IP  - 9
4099  - http://ard.bmj.com/content/63/9/1009.short
4100  - http://ard.bmj.com/content/63/9/1009.full
SO  - Ann Rheum Dis2004 Sep 01; 63
AB  - Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)—a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients.